Erste Group downgraded Eli Lilly from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $840.00 → $930.00 | Outperform | BMO Capital Markets |
| 10/14/2025 | Hold → Buy | Erste Group | |
| 9/17/2025 | $830.00 | Buy → Hold | Berenberg |
| 8/27/2025 | $700.00 | Reduce → Hold | HSBC Securities |
| 8/18/2025 | $700.00 | Outperform → Neutral | Daiwa Securities |
| 8/7/2025 | $715.00 | Outperform → Market Perform | Leerink Partners |
| 6/5/2025 | Buy → Hold | Erste Group | |
| 4/28/2025 | $1150.00 → $700.00 | Buy → Reduce | HSBC Securities |
8-K - ELI LILLY & Co (0000059478) (Filer)
FWP - ELI LILLY & Co (0000059478) (Subject)
10-Q - ELI LILLY & Co (0000059478) (Filer)
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve
New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared to approved monthly maintenance dosing Lilly submitted these data to the FDA for a potential label update for EBGLYSS If approved, EBGLYSS would be a first-line biologic that offers the option of monotherapy with once every eight-week maintenance dosing in moderate-to-severe atopic dermatitis uncontrolled by topicals INDIANAPOLIS, Oct. 24, 2025 /PRNewswire/ -- New results show Eli Lilly and Company's (NYSE:LLY) EBGLYSS (lebrikizumab-lbkz) sustained similar levels of skin clearance when administered as a single injection of
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show 71% of adolescents with severe disease treated with baricitinib 4 mg achieved successful scalp hair regrowth at one year, with continuous improvements observed throughout those 52 weeks Lilly intends to submit the BRAVE-AA-PEDS data to global regulators for a potential label update for baricitinib (commercially available as Olumiant) INDIANAPOLIS, Oct. 24, 2025 /PRNewswire/ -- New results from Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) showed once-daily, oral baricitinib 4 mg help
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
BMO Capital Markets reiterated coverage of Eli Lilly with a rating of Outperform and set a new price target of $930.00 from $840.00 previously
Erste Group upgraded Eli Lilly from Hold to Buy
Berenberg downgraded Eli Lilly from Buy to Hold and set a new price target of $830.00
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve
INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor."Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally," said David A. Ricks, Lilly's chair and CEO. "As leader of Lilly Neuroscience, Anne led the global launch of our first ever Alzh
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into heal
Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. Increased the midpoint of our 2025 full-year revenue guidance by $1.5 billion to be in the range of $60 billion to $62 billion; reported EPS guidance raised to be in the range of $20.85 to $22.10 and non-GAAP EPS guidance raised to be in the range $21.75 to $23.00.Pipeline progress included positive results in orforglipron for obesity, Mounjaro SURPASS CVOT for type 2 diabetes and heart disease, and Jaypirca H2H vs Imbruvica in CLL/SLL.Q2 2025 EPS increased 92% to $6.29 on a reported basis and increased 61% to $6.31 on a non-GAAP basis, both inclusive of $0.14 of acquired IPR&D charges.Busi
INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 8:30 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into hea